Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Endocrinology

Managing FH-II: Medication Goals and Safety

At a Glance

Familial hyperaldosteronism type II is usually managed with medicines called mineralocorticoid receptor antagonists rather than removal of both adrenal glands. Care focuses on blood pressure, safe potassium, renin response, and kidney monitoring.

Because CLCN2-associated Familial Hyperaldosteronism Type II (FH-II) typically affects both adrenal glands (bilateral), the preferred standard of care is medical management [1]. While surgery can often cure a single overactive gland, surgically removing both glands (bilateral adrenalectomy) is not usually recommended because it leaves you permanently dependent on life-sustaining hormone replacements [2][3]. Instead, doctors use a class of medications called Mineralocorticoid Receptor Antagonists (MRAs) to block the effects of excess aldosterone [4][5].

The Goals of Medical Treatment

Success in treating FH-II is an individualized balance. Your care team is generally aiming for three clinical targets [6][7]:

  1. Blood Pressure Control: Normalizing your blood pressure using the fewest necessary medications [6].
  2. Potassium Normalization: Maintaining a safe, individualized normal potassium level. Some patients need to completely avoid potassium supplements, while others may still require them [3][8].
  3. Renin “Unsuppression”: Watching your renin levels rise from baseline as a sign of adequate aldosterone blockade [6][9].

The Role of Renin

In untreated PA, your high aldosterone “suppresses” your renin to near-zero [10]. When you take an MRA, your body senses the aldosterone blockade and begins to produce renin again [6]. Many specialists look for a Plasma Renin Activity (PRA) of ≥1.0 ng/mL/hr as an observational target indicating adequate treatment [6][9]. However, this threshold is not a universal rule; it varies by assay and must be balanced against your blood pressure, kidney health, and medication side effects [9][11]. Never increase your MRA dose based on a renin or blood pressure reading at home without your clinician’s direct instruction.

Primary Medications for FH-II

Spironolactone (Aldactone)

This is usually the first-line MRA [4]. It is highly effective but can also interact with sex hormone receptors [4].

  • Side Effects to Watch: In men, it can cause gynecomastia (breast tissue growth) or erectile dysfunction [12]. In women, it can cause breast tenderness or menstrual irregularities [12]. Note: Spironolactone is generally avoided or specially managed during pregnancy; discuss family planning with your doctor early.

Eplerenone (Inspra)

If you cannot tolerate the side effects of spironolactone, eplerenone is a selective alternative [4][13]. It targets the aldosterone receptor specifically, avoiding most sex-hormone-related side effects [13].

  • Trade-off: It is typically more expensive, has a shorter half-life, and often requires twice-daily dosing [4][8].

Amiloride

While not an MRA, amiloride is a “potassium-sparing” diuretic that blocks a different channel in the kidney [14]. It is sometimes used as an add-on therapy [15].

Monitoring for Safety: Potassium and Kidneys

MRAs cause your body to hold onto potassium. While this helps correct hypokalemia, it creates a risk of hyperkalemia (dangerously high potassium), which can happen without warning symptoms [16][17].

  • Interactions: Avoid “salt substitutes” (which often contain potassium) and discuss all medications with your doctor. ACE inhibitors, ARBs, NSAIDs (like ibuprofen), and antibiotics like trimethoprim can drastically increase your risk of hyperkalemia when combined with an MRA.
  • Kidney Health (Creatinine): A modest rise in creatinine (or a drop in eGFR) can occur when starting an MRA as your kidney pressure adjusts. However, a rapid, substantial, or symptomatic change is not automatically benign. It could indicate acute kidney injury, volume depletion, or a drug interaction [18][19].

You will need laboratory blood tests soon after starting or changing your MRA dose. If you experience severe diarrhea/vomiting (dehydration), profound weakness, or palpitations, contact your care team immediately for guidance on adjusting your dose [20][21].

Common questions in this guide

Why is medication usually preferred over removing both adrenal glands in FH-II?
FH-II typically affects both adrenal glands, so removing both would cause permanent dependence on hormone replacement. Medicines called mineralocorticoid receptor antagonists block aldosterone's effects while preserving the adrenal glands, making long-term medical treatment the usual approach.
What are doctors trying to achieve with FH-II treatment?
The main goals are to control blood pressure, keep potassium in a safe individualized range, and reduce the effects of excess aldosterone. Clinicians may also look for suppressed renin to rise, but renin targets vary and must be considered alongside kidney function, blood pressure, and side effects.
Does a renin level of 1.0 mean my FH-II medicine dose is right?
A plasma renin activity of at least 1.0 ng/mL/hr is sometimes used as an observational target, not a universal dosing rule. The result depends on the test and must be weighed with blood pressure, potassium, kidney health, and side effects. Do not change your dose based on a home reading without clinician instruction.
Which medicines are used to treat familial hyperaldosteronism type II?
Spironolactone is often the first mineralocorticoid receptor antagonist used. Eplerenone is a more selective alternative when spironolactone causes sex hormone-related effects, while amiloride may be added in some cases. The choice and dose depend on your response, potassium, kidney function, and other medicines.
Why do I need potassium and kidney blood tests after starting an MRA?
MRAs can raise potassium, sometimes without warning symptoms, and kidney function can change after treatment begins or the dose changes. Blood tests check potassium and measures such as creatinine and eGFR so your clinician can adjust treatment safely. Salt substitutes and some medicines can increase these risks.
What medicines and symptoms should I discuss urgently while taking an MRA?
Tell your care team about salt substitutes, potassium supplements, ACE inhibitors, ARBs, NSAIDs such as ibuprofen, and trimethoprim because they can increase the risk of high potassium or kidney problems. Contact the team promptly for severe vomiting or diarrhea, profound weakness, or palpitations, especially after dehydration. Do not stop or change prescribed medicines without guidance.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Familial hyperaldosteronism type II.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my most recent Plasma Renin Activity (PRA) or Direct Renin Concentration, and is it a helpful target for adjusting my medication?
  2. 2.If my renin is still low despite normal blood pressure, should we discuss adjusting my MRA dose, or are we limited by my potassium or kidney function?
  3. 3.Given my diagnosis, is there any exceptional reason we would consider bilateral adrenalectomy, or is long-term medication the definite plan?
  4. 4.Can we re-evaluate my need for potassium supplements now that I am on an MRA?
  5. 5.What change in my creatinine, eGFR, or potassium levels should prompt me to call you immediately?

References

References (21)
  1. 1

    Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels.

    Stowasser M, Wolley M, Wu A, et al.

    Current hypertension reports 2019; (21(4)):31 doi:10.1007/s11906-019-0934-y.

    PMID: 30949771
  2. 2

    The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

    Funder JW, Carey RM, Mantero F, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(5)):1889-916 doi:10.1210/jc.2015-4061.

    PMID: 26934393
  3. 3

    Diagnosis and treatment of primary aldosteronism: practical clinical perspectives.

    Young WF

    Journal of internal medicine 2019; (285(2)):126-148 doi:10.1111/joim.12831.

    PMID: 30255616
  4. 4

    Taiwan mini-frontier of primary aldosteronism: Updating treatment and comorbidities detection.

    Chan CK, Chang YY, Tsai YC, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2021; (120(10)):1811-1820 doi:10.1016/j.jfma.2021.03.032.

    PMID: 33906783
  5. 5

    Diagnosis and management of primary aldosteronism.

    Vilela LAP, Almeida MQ

    Archives of endocrinology and metabolism 2017; (61(3)):305-312 doi:10.1590/2359-3997000000274.

    PMID: 28699986
  6. 6

    Treatment of Primary Aldosteronism.

    Parisien-La Salle S, Hundemer GL, Nehs MA, et al.

    Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e26238 doi:10.1161/HYPERTENSIONAHA.126.26238.

    PMID: 41808633
  7. 7

    Biomarkers to Guide Medical Therapy in Primary Aldosteronism.

    Hundemer GL, Leung AA, Kline GA, et al.

    Endocrine reviews 2024; (45(1)):69-94 doi:10.1210/endrev/bnad024.

    PMID: 37439256
  8. 8

    Primary aldosteronism.

    Vaidya A, Kline GA, Mulatero P, et al.

    Nature reviews. Disease primers 2026; (12(1)).

    PMID: 42350437
  9. 9

    Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.

    Hundemer GL, Curhan GC, Yozamp N, et al.

    The lancet. Diabetes & endocrinology 2018; (6(1)):51-59 doi:10.1016/S2213-8587(17)30367-4.

    PMID: 29129576
  10. 10

    Evaluation of Current Screening Thresholds for the Detection of Primary Aldosteronism.

    Voorhies KR, Bi C, Adeyemo MA, et al.

    Hypertension (Dallas, Tex. : 1979) 2026; doi:10.1161/HYPERTENSIONAHA.126.27634.

    PMID: 42751802
  11. 11

    Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.

    Hundemer GL, Curhan GC, Yozamp N, et al.

    JAMA cardiology 2018; (3(8)):768-774 doi:10.1001/jamacardio.2018.2003.

    PMID: 30027227
  12. 12

    Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.

    Seferovic PM, Pelliccia F, Zivkovic I, et al.

    International journal of cardiology 2015; (200()):3-7.

    PMID: 26404746
  13. 13

    Amiloride: revisiting an old drug for resistant hypertension.

    Lee CJ, Park S

    Clinical hypertension 2025; (31()):e42 doi:10.5646/ch.2025.31.e42.

    PMID: 41362675
  14. 14

    Outcomes of drug-based and surgical treatments for primary aldosteronism.

    Steichen O, Lorthioir A, Zinzindohoue F, et al.

    Advances in chronic kidney disease 2015; (22(3)):196-203.

    PMID: 25908468
  15. 15

    Primary Aldosteronism: Present and Future.

    Funder JW

    Vitamins and hormones 2019; (109()):285-302 doi:10.1016/bs.vh.2018.10.006.

    PMID: 30678860
  16. 16

    Adverse Effects of Mineralocorticoid Receptor Antagonist Administration.

    Kallistratos MS, Pittaras A, Theodoulidis I, et al.

    Current pharmaceutical design 2018; (24(46)):5537-5541 doi:10.2174/1381612825666190222144359.

    PMID: 30799782
  17. 17

    Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.

    Kolkhof P, Joseph A, Kintscher U

    Pharmacological research 2021; (172()):105859 doi:10.1016/j.phrs.2021.105859.

    PMID: 34461222
  18. 18

    Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function.

    Kobayashi H, Abe M, Nakamura Y, et al.

    Hypertension (Dallas, Tex. : 1979) 2019; (74(3)):630-638 doi:10.1161/HYPERTENSIONAHA.119.13131.

    PMID: 31327258
  19. 19

    Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.

    Katsuragawa S, Goto A, Shinoda S, et al.

    Hypertension (Dallas, Tex. : 1979) 2023; (80(9)):1909-1920 doi:10.1161/HYPERTENSIONAHA.123.21096.

    PMID: 37449450
  20. 20

    Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

    Lainscak M, Pelliccia F, Rosano G, et al.

    International journal of cardiology 2015; (200()):25-9.

    PMID: 26404748
  21. 21

    Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?

    Manolis AA, Manolis TA, Melita H, Manolis AS

    Current hypertension reports 2019; (21(3)):22 doi:10.1007/s11906-019-0924-0.

    PMID: 30826898

This page explains FH-II medication goals and safety monitoring for informational purposes only and does not constitute medical advice. Do not change MRA doses, potassium supplements, or other medicines without guidance from your clinician.